Coherus BioSciences (CHRS) Projected to Post Earnings on Monday

Coherus BioSciences (NASDAQ:CHRS - Get Free Report) will likely be posting its quarterly earnings results before the market opens on Monday, March 10th. Analysts expect Coherus BioSciences to post earnings of ($0.10) per share and revenue of $43.88 million for the quarter. Persons that wish to listen to the company's earnings conference call can do so using this link.

Coherus BioSciences Stock Up 4.5 %

NASDAQ:CHRS traded up $0.05 on Friday, hitting $1.04. The stock had a trading volume of 2,045,917 shares, compared to its average volume of 1,881,348. Coherus BioSciences has a 52 week low of $0.66 and a 52 week high of $2.64. The business's fifty day moving average is $1.26 and its 200 day moving average is $1.19. The company has a market cap of $120.53 million, a PE ratio of -13.00 and a beta of 0.92.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $7.00 price objective on shares of Coherus BioSciences in a research note on Thursday, January 23rd. Robert W. Baird raised their price target on shares of Coherus BioSciences from $4.00 to $6.00 and gave the company an "outperform" rating in a research report on Thursday, December 5th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $5.38.

Remove Ads

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.